Status:

COMPLETED

Lipoprotein Turnover on Low- and High-MUFA Portfolio Diets

Lead Sponsor:

University of Toronto

Collaborating Sponsors:

Canadian Institutes of Health Research (CIHR)

Conditions:

Hyperlipidemia

Cardiovascular Diseases

Eligibility:

All Genders

21-70 years

Phase:

PHASE2

Brief Summary

Low and very low carbohydrate diets, such as the Atkins' Diet, have recently gained attention for their potential health benefits from weight loss and have gained some scientific support from a growin...

Detailed Description

All subjects will undergo two parallel 2-phase treatments. On one treatment, subjects will be placed on a low fat diet for one month (control run-in diet) and then for the second month will continue o...

Eligibility Criteria

Inclusion

  • men and postmenopausal women
  • Body mass index \> 18.5 kg/m2 and \< 40 kg/m2
  • Fasting plasma triglyceride (TG) concentration \> 2.5 mmol/l and \< 6.0 mmol/l at recruitment.
  • Fasting plasma LDL cholesterol concentration \> 3.4 mmol/l at recruitment.
  • Fasting plasma HDL cholesterol concentration \< 1.0 mmol/l at recruitment.
  • living within a 40 km radius of St. Michael's Hospital.

Exclusion

  • Premenopausal women will be excluded due to the fluctuation of blood lipids during the menstrual cycle and the difficulty of synchronising the timing of three one month studies with the same point in the menstrual cycle.
  • Taking cholesterol medications at the start of the study. However, with their physician's approval those who wish to join but are already taking cholesterol-lowering medications (or cholesterol lowering natural health products) may join the study providing the medications (or natural health products) are stopped for at least 2 weeks before starting the study and throughout the study.
  • Patients with uncontrolled high blood pressure will be excluded. The cut off for raised blood pressure has been taken as greater than 140/90mmHg. Patients with systolic blood pressure between 140-150mmHg and diastolic blood pressure between 90-95mmHg may be accepted, since we have found that on the diet their blood pressures tend to be lowered into the acceptable range. For patients in the above normal range (as above), a letter will be required from the physician responsible for their care.
  • Changing the type or dose of their drug treatment during the study.
  • Those judged as having a likelihood of being non-compliant with instructions for whatever reason. Those with low compliance to lipid-lowering therapy will not be selected.
  • Food allergies
  • Evidence or history of diabetes, renal liver disease or gastrointestinal disease. Patients will be excluded if they have gross xanthoma or advanced premature cardiovascular disease since this group may include hyperabsorbers of plant sterols.
  • Patients with major cardiovascular event (stroke or myocardial infarction), with secondary causes of hypercholesterolemia (or untreated hypothyroidism), with uncontrolled blood pressure, major disability or disorder such as liver disease, renal failure or with major surgery \< 6 months prior to randomization. Individuals predisposed to hemorrhagic stroke (on the basis of untreated raised blood pressure) will also be excluded.
  • Antibiotic use within the last three months.
  • Hormone replacement therapy.
  • Smokers or have significant alcohol intake (\>1 drink/d).
  • Disallowed medications will be cholesterol lowering drugs which if prescribed by patients' physicians while on the study will be a reason for discontinuation from the study. Introduction of cholesterol lowering natural health products during the study will also be a reason for withdrawing a participant from the study.
  • individuals with acute (\<6 weeks) or chronic (\>6 weeks) infections, either bacterial or viral, or individuals suffering from chronic inflammatory diseases

Key Trial Info

Start Date :

April 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2009

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT00430430

Start Date

April 1 2007

End Date

April 1 2009

Last Update

October 27 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Risk Factor Modification Centre, St. Michael's Hospital

Toronto, Ontario, Canada, M5C 2T2